A kind of iopromide synthesis method
Iodine isophthalyl chloride by reacting the intermediate 5-methoxyacetamide-2,4,6-triiodoisophthalyl chloride with 1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole to produce iodine Promide active ester intermediate, and purified by beating, the problem of the instability of intermediate acid chloride and symmetric disubstituted impurities in the synthesis of iodine promide in the prior art is solved, and the high purity and high yield of iodine is achieved. Promide production reduces production costs and improves medicinal safety.
Patent Information
- Application Number
- CN202111609147.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-27
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2041-12-27
AI Technical Summary
In the existing iodopromide synthesis method, the instability of intermediate acid chloride and the difficulty of separation of symmetric disubstituted impurities lead to low purity of the product and high production cost. The symmetric disubstituted by-products are similar to that of iodopromide, making it difficult to separate. Impacts medicinal safety.
The intermediate 5-methoxyacetamide-2,4,6-triiodoisophthalyl chloride reacts with 1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole to produce iopropion The amine-active ester intermediate is isolated and purified by beating to reduce the formation of hydrolysate and significantly improve the purity and yield.
It has achieved high purity and high yield of iodopreamine production, reduced production costs, met pharmaceutical standards, and is suitable for the industrial production of iodopreamine injections.
Smart Images

Figure SMS_3
Abstract
Description
Technical Field
[0001] The invention relates to a method for synthesizing iopromide and belongs to the field of pharmaceutical chemistry. Background Art
[0002] Iopromide is a non-ionic contrast agent developed by Schering AG of Germany. Its trade name is Ultravist. Due to its few adverse reactions and good safety, its sales volume ranks among the top in the global contrast agent market. Summary of the invention
[0003] The general synthesis method of iopromide is reported in U.S. Patent No. 4364921, which uses 5-amino-2,4,6-triiodoisophthalic acid as the starting material, chlorinates with thionyl chloride to obtain an intermediate 5-amino-2,4,6-triiodoisophthalic acid chloride, and then undergoes an acylation reaction with methoxyacetyl chloride to obtain an intermediate 5-methoxyacetamido-2,4,6-triiodoisophthalic acid chloride, which is then ammonolyzed with 3-amino-1,2-propylene glycol to obtain an intermediate N-(2,3-dihydroxy-1-propyl)-5-methoxyacetamido-3-chloroformyl-2,4,6-triiodobenzamide, which is finally ammonolyzed with 3-methylamino-1,2-propylene glycol and purified to obtain iopromide.
[0004] The synthetic route is as follows:
[0005] .
[0006] The synthetic route of this method has short steps and is relatively simple to operate. The structural characteristics of iopromide are different from those of most contrast agents in that the two dihydroxypropionamide structures of the benzene ring are asymmetric structures, one of which is substituted by a hydrogen atom and the other by a methyl group. Therefore, in the process of synthesizing the acyl chloride intermediate (compound 2), a large amount of symmetrical disubstituted impurities (compounds 3 and 4) are inevitably produced. As follows:
[0007] .
[0008] The symmetrical disubstituted impurity structure (compound 3 and compound 4) is similar to iopromide and needs to be removed by multiple recrystallizations or separated and purified by macroporous resin columns. Chinese patent CN102351735 reports that a large amount of organic solvents need to be used for multiple crystallizations and purifications, which is cumbersome, reduces the product yield, and increases the production cost. Therefore, it is necessary to remove the symmetrical disubstituted byproducts through an economical and effective method to obtain iopromide with high yield and high purity to meet the needs of iopromide production.
[0009] In order to solve the shortcomings of the existing synthesis methods, our company has discovered a new synthesis method, namely, the intermediate 5-methoxyacetamido-2,4,6-triiodoisophthaloyl chloride is reacted with 3-amino-1,2-propanediol or 3-methylamino-1,2-propanediol to obtain the acyl chloride intermediate (Compound 3 and Compound 4), and then reacted with 1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole to obtain the iopromide intermediate active ester (Compound 1 and Compound 2), which is separated and purified, and then reacted with 3-methylamino-1,2-propanediol or 3-amino-1,2-propanediol, and purified by macroporous resin to obtain iopromide.
[0010] The synthetic route is as follows:
[0011] Wherein R2 represents a hydrogen atom or a nitrogen atom.
[0012] Generally, since the reaction activity of acyl chloride is higher than that of active ester, it can directly react with amino-containing substrates to form amides, without the need to convert the acyl chloride into active esters for further reaction. However, in the synthesis of iopromide, the acyl chloride intermediate (compound 2) is unstable in nature, and more hydrolysis products will be produced during the separation process from the symmetrically disubstituted impurities, introducing new impurities. Therefore, it is not feasible to directly separate the acyl chloride intermediate in industrial production.
[0013] In the experiment, we found that the acid chloride intermediate can react mildly with 1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole and completely convert into the corresponding iopromide active ester intermediate, which has obvious difference in solubility from symmetrical disubstituted impurities. The iopromide intermediate active ester has very low solubility in water, while the iopromide symmetrical disubstituted impurity can form hydrogen bonds with polar solvents due to the presence of multiple hydroxyl functional groups in the structure, and is easily soluble in water. The two can be effectively separated by simply beating with water or aqueous methanol or aqueous ethanol. Since the reaction activity of the iopromide active ester intermediate is lower than that of the acid chloride, no hydrolysis products will be produced during the beating process to increase new impurities.
[0014] According to the present invention, a crystalline iopromide intermediate active ester can be obtained by simple pulping, and the symmetrical disubstituted by-products that cause the purity of iopromide to decrease can be easily removed without the need for additional purification steps. High-purity iopromide can be obtained with a high yield, which significantly reduces the production cost and is more suitable for industrial production.
[0015] Since iopromide and impurities have similar structures and are difficult to separate, the purity requirements of iopromide API for pharmaceutical use are relatively low and the impurity limit is relatively high (such as USP43 stipulates that the total impurities of iopromide are less than 3.0%). However, the dosage of iopromide injection used as a contrast agent is very large, and common specifications include (62.34g / 100ml, 76.89 / 100ml, etc.), and the total amount of impurities is large, which may cause more adverse reactions and affect the safety of medication. The iopromide API obtained by the present invention has high purity, total impurities <0.5%, and quality standards that exceed existing pharmacopoeia standards (such as USP43 / EP10.0 / BP2021), and is suitable for the production of iopromide injection.
[0016] The present invention is further described below by way of examples and comparative examples. In addition to the following examples, various substitutions or changes made according to common technical knowledge and conventional means in the art are all included in the scope of the present invention. Specific embodiments
[0017] Step 1 Preparation of iopromide intermediate active ester (Compound 1)
[0018] Example 1: In a three-necked flask, add 30g of 5-methoxyacetamido-2,4,6-triiodoisophthaloyl chloride, 100ml of dimethylacetamide and 9ml of diisopropylethylamine, stir to dissolve, then add 4.5g of 3-amino-1,2-propylene glycol, react at 10-20°C for 8 hours, then add 7.9g of 1-hydroxybenzotriazole and 9.3g of potassium carbonate, react at 20-30°C for 2 hours. Filter to remove inorganic salts, concentrate the filtrate under reduced pressure, add 200ml of water to the residue, beat at 10-20°C for 2 hours, filter, and obtain 25.8g of iopromide intermediate active ester.
[0019] Example 2: In a three-necked flask, add 30 g of 5-methoxyacetamido-2,4,6-triiodoisophthaloyl chloride, 100 ml of dimethylacetamide, and 9 ml of diisopropylethylamine, stir to dissolve, then add 4.5 g of 3-amino-1,2-propylene glycol, react at 10-20°C for 8 hours, then add 7.9 g of 1-hydroxy-7-azabenzotriazole and 9.3 g of potassium carbonate, and react at 20-30°C for 2 hours. Filter to remove inorganic salts, concentrate the filtrate under reduced pressure, add 50 ml of methanol and 200 ml of water to the residue, beat at 10-20°C for 2 hours, filter, and obtain 24.2 g of iopromide intermediate active ester.
[0020] Step 1: Preparation of the active ester of iopromide intermediate (Compound 2)
[0021] Example 3: In a three-necked flask, add 50 g of 5-methoxyacetamido-2,4,6-triiodoisophthaloyl chloride, 150 ml of dimethylacetamide, and 15 ml of diisopropylethylamine, stir to dissolve, then add 9.5 g of 3-methylamino-1,2-propylene glycol, react at 10-20°C for 6 hours, then add 13 g of 1-hydroxybenzotriazole and 15.5 g of potassium carbonate, and react at 20-30°C for 2 hours. Filter to remove inorganic salts, concentrate the filtrate under reduced pressure, add 100 ml of 95% ethanol and 100 ml of water to the residue, beat at 10-20°C for 2 hours, filter, and obtain 22.6 g of iopromide intermediate active ester.
[0022] Example 4: In a three-necked flask, add 50 g of 5-methoxyacetamido-2,4,6-triiodoisophthaloyl chloride, 150 ml of dimethylacetamide, and 15 ml of diisopropylethylamine, stir to dissolve, then add 9.5 g of 3-methylamino-1,2-propylene glycol, react at 10-20°C for 6 hours, then add 13 g of 1-hydroxy-7-azabenzotriazole and 15.5 g of potassium carbonate, react at 20-30°C for 2 hours. Filter to remove inorganic salts, concentrate the filtrate under reduced pressure, add 100 ml of 95% ethanol and 100 ml of water to the residue, beat at 10-20°C for 2 hours, filter, and obtain 23.1 g of iopromide intermediate active ester.
[0023] Step 2: Synthesis of Iopromide
[0024] Example 5: In a three-necked flask, add 20g of the active ester of the iopromide intermediate obtained in Example 1, 100ml of dimethylacetamide, and 4.8ml of diisopropylethylamine, stir to dissolve, then add 5.1g of 3-methylamino-1,2-propylene glycol, raise the temperature to 70-80°C and react for 8 hours. Then, the filtrate is concentrated under reduced pressure, water is added to the residue to dissolve, activated carbon is decolorized and filtered, and the obtained solution is purified by a macroporous resin column equipped with XAD1600 to obtain 15.8g of iopromide with a purity of 99.76%.
[0025] Example 6: In a three-necked flask, add 20g of the active ester of the iopromide intermediate obtained in Example 2, 100ml of dimethylacetamide, and 4.8ml of diisopropylethylamine, stir to dissolve, then add 5.1g of 3-methylamino-1,2-propylene glycol, raise the temperature to 70-80°C and react for 8 hours. Then, the filtrate is concentrated under reduced pressure, water is added to the residue to dissolve, activated carbon is decolorized and filtered, and the obtained solution is purified by a macroporous resin column equipped with XAD1600 to obtain 16.3g of iopromide with a purity of 99.81%.
[0026] Example 7: In a three-necked flask, add 35g of the active ester of the iopromide intermediate obtained in Example 3, 180ml of dimethylacetamide, and 8.5ml of diisopropylethylamine, stir to dissolve, then add 7.8g of 3-amino-1,2-propylene glycol, raise the temperature to 70-80°C and react for 12 hours. Then, the filtrate is concentrated under reduced pressure, water is added to the residue to dissolve, activated carbon is decolorized and filtered, and the obtained solution is purified by a macroporous resin column equipped with XAD1600 to obtain 26.3g of iopromide with a purity of 99.72%.
[0027] Example 8: In a three-necked flask, add 35g of the active ester of the iopromide intermediate obtained in Example 4, 180ml of dimethylacetamide, and 8.5ml of diisopropylethylamine, stir to dissolve, then add 7.8g of 3-amino-1,2-propylene glycol, raise the temperature to 70-80°C and react for 12 hours. Then, the filtrate is concentrated under reduced pressure, water is added to the residue to dissolve, activated carbon is decolorized and filtered, and the obtained solution is purified by a macroporous resin column equipped with XAD1600 to obtain 27.2g of iopromide with a purity of 99.65%.
[0028] Example 9: Production of injection using the iopromide synthesized by the present invention
[0029] Prescription composition:
[0030] Iopromide 7689g
[0031] Tromethamine 24.2g
[0032] Edetate calcium sodium 1.0g
[0033] 10% hydrochloric acid
[0034] Add water for injection to 10.0L
[0035] Operation: Add iopromide, tromethamine, calcium sodium edetate and about 80% water into the preparation tank, heat to dissolve, adjust the pH to 7.2-7.8 with 10% hydrochloric acid, filter, add water for injection to the full amount, stir evenly, filter through a sterilizing filter, fill, and then sterilize in a sterilizer to obtain iopromide injection.
Claims
1. A method for synthesizing iopromide, Its characteristics are Iopromide is synthesized by the following chemical reaction, i.e., 5-methoxyacetamido-2,4,6-triiodoisophthaloyl chloride is reacted with 3-amino-1,2-propylene glycol to obtain an acyl chloride intermediate, which is reacted with 1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole to obtain an ioopromide intermediate active ester, which is separated and purified and then reacted with 3-methylamino-1,2-propylene glycol to obtain ioopromide; or a method for synthesizing ioopromide, characterized in that ioopromide is synthesized by the following chemical reaction, i.e., 5-methoxyacetamido-2,4,6-triiodoisophthaloyl chloride is reacted with 3-methylamino-1,2-propylene glycol to obtain an acyl chloride intermediate, which is reacted with 1-hydroxybenzotriazole or 1-hydroxy-7-azabenzotriazole to obtain an ioopromide intermediate active ester, which is separated and purified and then reacted with 3-amino-1,2-propylene glycol to obtain ioopromide.
Citation Information
Patent Citations
Novel triiodinated isophthalic acid diamides as nonionic X-ray contrast media
US4364921A
Iopromide preparation method
CN105001113A
New method for preparing iopromide
CN105017062A
